Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Building A Context-Driven Architecture Into Pharma Commercial Stacks
Sahitya Sridhar, Co-Founder, SynthioLabs. For the past decade, pharma's commercial transformation has followed a familiar playbook: Digitize engagement, add more channels and layer analytics on top. Customer relationship management (CRM) systems…
India's Top Bank in $1 Billion Funding for Sun Pharma's US Deal
State Bank of India plans to join a group of global lenders in funding Sun Pharmaceutical Industries Ltd. 's $12 billion overseas acquisition, according to people familiar with the matter. SBI, the country's largest bank by assets, is set to commit…
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of companies is capitalizing on space, which allows…
Fonds de solidarité FTQ Invests in CELYSTRA Pharma
Investment is part of a $20 million financing round MONTRÉAL, June 9, 2026 /CNW/ - To support the launch of CELYSTRA Pharma, the Fonds de solidarité FTQ has joined the company's founders and other investors in a $20 million financing…
AI Vaccine Clears Human Trials, Handing Pharma a New Playbook
The vaccine, developed by the University of Cambridge and its spinout DIOSynVax, was found safe and well tolerated, ScienceDaily reported Friday (June 5). The AI model didn't work from a known pathogen. It analyzed surveillance data from virus…
TD Asset Management Inc Boosts Stake in BridgeBio Pharma, Inc. $BBIO
TD Asset Management Inc increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 62.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 144,180 shares of the company's stock…
Capital World Investors Raises Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS
Capital World Investors raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The…
Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX
Prudential PLC trimmed its position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 94.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,575 shares of the…
Erste Asset Management GmbH Trims Holdings in BridgeBio Pharma, Inc. $BBIO
Erste Asset Management GmbH lessened its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 21.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission…
PDA Announces Glenn E. Wright is Stepping Down as CEO & President on June 30, 2026; Craig Elliott Assuming Role Effective July 1, 2026
'Leading PDA and ensuring we maintained a clear focus on our members and mission has been an extremely rewarding experience—one I will miss greatly,' said Wright. Wright's legacy speaks for itself. Nearly four decades of commitment to PDA's…
India Inc Battles Rising Gulf War Costs
Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on. Prolonged West Asia conflict is raising freight, insurance and input costs across multiple sectors of India Inc. Automobile and…
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
LONDON — GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm continues its expansion in oncology. The deal is the latest in a run of biopharma acquisitions in recent months, as…
The Inside Story Of The World's First Cannabis-Based Painkiller
A new botanical drug derived from marijuana has been approved in Germany to treat chronic pain, ushering in a new future for the medical applications of cannabis. In late May, Germany's Federal Institute for Drugs and Medical Devices, which is…
Eli Lilly: Bears Are Missing The Underlying Thesis (NYSE:LLY)
Eli Lilly is leveraging its GLP-1-driven cash flow to build transformative AI and biotech infrastructure, not just dominating the current obesity market. LLY's R&D intensity, AI-driven LillyPod platform, and TuneLab ecosystem position the company…
Tempus AI: A Unique AI Business Model With Asymmetric Upside (NASDAQ:TEM)
Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma…
Receive a Daily briefing on Pharma Industry News
Get Started